Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. ResApp Health Limited
  6. News
  7. Summary
    RAP   AU000000RAP5


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ResApp Health : Medgate extends European ResAppDx trial

06/03/2021 | 12:47am EDT

View printer-friendly version

Brisbane, Australia, 3 June 2021 - ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, today provides an update on Medgate AG's ('Medgate') pilot trial of ResApp's smartphone-based acute respiratory diagnostic test ResAppDx across its telemedicine services.

Medgate commenced a pilot trial of ResApp's smartphone-based acute respiratory diagnostic test ResAppDx across its telemedicine services in March 2021 (refer ASX announcement: 4 March 2021).

Following an interim review, Medgate and ResApp have decided to extend the pilot by two months. This additional time will be used to collect further data and optimise Medgate's integration of ResAppDx within its telemedicine services.

CEO and Managing Director, Dr Tony Keating said: 'Medgate and our clinical experts have found the data collected during the initial pilot period was consistent with the data from our extensive clinical studies, further demonstrating the accuracy of our cough-based diagnostic technology. We also continue our negotiations with Medgate for the commercial deployment of ResAppDx.

'Medgate has made a strong commitment to ResApp and both parties remain confident of a successful outcome. We are very appreciative of the ongoing support and insights provided by the team at Medgate and look forward to a continued innovative and mutually beneficial relationship.'

Dr Andy Fischer, CEO Medgate said: ''Our preliminary data is consistent with ResApp's clinical study results and we received positive feedback from our patients regarding their experience with the ResAppDx test. We are extending the pilot to gain more experience and further optimise our workflows to maximise the benefits of ResAppDx for Medgate and its patients.''


About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.

About Medgate AG
Medgate brings the physician to where he or she is needed by patients and relies on Digital Health solutions to do so. The focus is on the well-being of the patient and the benefits to society. Medgate was founded in Switzerland in 1999 and today employs over 510 people worldwide. Since 2000, Medgate has been operating the largest medical telemedicine center in Europe and thus has an extraordinary amount of experience and knowledge in telemedicine. Medgate is also present in Germany, the Philippines and the United Arab Emirates. www.medgate.care


ResApp Health Limited published this content on 03 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 June 2021 04:46:03 UTC.

© Publicnow 2021
07/05RESAPP HEALTH : Commercial agreement with Doctors on Demand in Australia
07/04Resapp Health Limited Signs A Commercial Agreement with Australian-Based Tele..
06/03RESAPP HEALTH : Medgate extends European ResAppDx trial
06/02Medgate Extends European ResAppDx Trial
05/17RESAPP HEALTH : Recruits First Participant in COVID-19 Study; Shares Jump 6%
05/16ResApp Health Limited Reports Recruited the First Participant in Its US-Based..
05/04RESAPP HEALTH : Signs Distribution Deal for Smartphone Diagnostic App in Kenya; ..
05/03RESAPP HEALTH : Agreement secured with Ilara Health to sell ResAppDx in Kenya
05/03Agreement with Ilara Health to sell ResAppDx in Kenya
04/12RESAPP HEALTH : Raises Over $4 Million in Placement
More news
Sales 2020 - - -
Net income 2020 -8,47 M -6,22 M -6,22 M
Net cash 2020 5,45 M 4,00 M 4,00 M
P/E ratio 2020 -14,6x
Yield 2020 -
Capitalization 34,4 M 25,2 M 25,2 M
EV / Sales 2019 -
EV / Sales 2020 -
Nbr of Employees 500
Free-Float 95,7%
Duration : Period :
ResApp Health Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RESAPP HEALTH LIMITED
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus -
Number of Analysts
Last Close Price 0,04 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Tony Keating Chief Executive Officer, Executive Director & MD
Roger Aston Non-Executive Chairman
Udantha Abeyratne Chief Scientist
Rob Keniger Vice President-Technology
Christopher Ntoumenopoulos Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
SAP SE12.70%169 087
INTUIT INC.38.35%144 819
SERVICENOW, INC.6.81%116 482
DOCUSIGN, INC.34.07%58 069